Teva's second-quarter sales soar after Barr integration
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries' acquisition of Barr Pharmaceuticals drove the Israeli company's net sales up by 20% to $3.4 billion in the second quarter.